Archived 15: Summary of National Advisory Committee on Immunization (NACI) updates of July 2, 2021

Notice to reader

This is an archived version. Please refer to current COVID-19 vaccine pages:

On this page

mRNA COVID-19 vaccines and myocarditis

NACI is now also recommending the following:

To see the full update, please visit NACI Recommendations on the use of COVID-19 vaccines.

What you need to know


“We continue to see risk from COVID-19 in our communities, and although adult vaccine coverage is growing daily, there have been recent outbreaks among adolescents in Canada and internationally. It is important for adolescents to continue getting vaccinated, particularly in the context of the Delta variant emerging in Canada.”

“We have been closely monitoring the evolving situation of rare cases of myocarditis or pericarditis following mRNA vaccination among younger people. NACI is encouraged to see that the clinical presentations appear mild, and resolve quickly. The benefits of the COVID-19 immunization program continue to outweigh the relatively small risk for all people including adolescents. It will be important for informed consent to include a discussion about what to watch for after vaccination and to seek medical care if symptoms develop. As a precaution, anyone who experiences myocarditis or pericarditis after the first dose should wait for us to learn more before getting a second dose.”
Dr. Shelley Deeks, NACI Chair

“There have been a small number of cases of myocarditis and pericarditis reported in Canada after vaccination. Evidence is evolving, and Canadian and international investigations into an association between myocarditis/pericarditis and mRNA vaccines continue. I want to let Canadians know that the benefits of mRNA COVID-19 vaccines continue to outweigh their potential risks. It is important that everyone gets their second vaccine dose to provide the best protection. The Government of Canada encourages people to get vaccinated and complete their vaccine series as soon as they are eligible.”
Dr. Theresa Tam, Chief Public Health Officer

NACI forward agenda

NACI continues to actively review emerging evidence on COVID-19 vaccines. Upcoming recommendation may include new advice on:

Page details

Date modified: